Fractyl Health accelerates REMAIN-1 study, expands REVITALIZE-1 eligibility

FRACTYL HEALTH, INC.

REMAIN-1 weight maintenance study accelerated; open-label REVEAL-1 data expected Q4 2024.
Midpoint data analysis for REMAIN-1 now anticipated in Q2 2025.
FDA approved protocol amendment for REVITALIZE-1: expands eligibility to any glucose lowering agent; potential U.S. treatment population ~6x to ~25M patients.
Topline data from REVITALIZE-1 expected mid-2025.
Preclinical data for Rejuva gene therapy vs semaglutide showed greater, more durable weight loss in mice; presented at ADA 84th Scientific Sessions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.